Foresee Pharmaceuticals Co., Ltd. (TPEX: 6576)

Market Cap	11.75B
Revenue (ttm)	346.56M
Net Income (ttm)	-930.72M
Shares Out	154.78M
EPS (ttm)	-6.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,407
Open	76.30
Previous Close	75.90
Day's Range	75.60 - 76.30
52-Week Range	68.40 - 107.50
Beta	1.11
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 24, 2025

About Foresee Pharmaceuticals

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6576

Financial Performance

In 2023, Foresee Pharmaceuticals's revenue was 195.04 million, a decrease of -35.31% compared to the previous year's 301.51 million. Losses were -1.04 billion, 119.3% more than in 2022.